We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Panel Improves Diagnosis of Candida in Pediatric Patients

By LabMedica International staff writers
Posted on 15 Jul 2015
Print article
In an investigational study of pediatric patients, a Candida test panel provided accurate, fast diagnosis with only 2 mL of blood.

Rapid detection of Candida enables faster initiation of targeted treatment and can reduce a patient's length of hospitalization by almost 9 days. A rapid negative result can prevent unnecessary administration of antimicrobials as well as prevent or reduce antimicrobial resistance.

T2 Biosystems, Inc. (Lexington, MA, USA) presented results from an investigational study evaluating its T2Candida Panel in pediatric patients at the 2015 American Society for Microbiology (ASM) general meeting in New Orleans (LA, USA). The study included 15 confirmed candidemia patients 5–12 years of age. The data presented showed that in each of the 15 patient samples, T2Candida was able to accurately identify the species in 3–5 hours, compared to 2–6 days for blood culture. For this study a manual pipetting protocol was adapted to enable detection from just 2 mL of blood compared to the 3 mL currently required for the standard loading procedure.

"Fast and accurate results have been a challenge to obtain in pediatric patients suspected of sepsis due to the volume of blood required by current diagnostic procedures," said Prof. Camille Hamula, Icahn School of Medicine, Mount Sinai Hospital, "This new loading procedure maintains the high accuracy and fast results of the T2Candida Panel but with lower sample volume, which could have an important impact on the lives of young patients at risk of sepsis." "We are encouraged by these findings demonstrating that our T2Candida Panel was able to provide accurate results from lower blood volumes, which is critical in the pediatric patient population," said John McDonough, T2 Biosystems president and CEO.

T2Candida Panel, the first sepsis pathogen diagnostic that provides species-specific results in 3–5 hours without need for blood culture, was cleared for marketing by the US Food and Drug Administration (FDA) in September 2014. T2Candida Panel performance was established in adult subjects; performance in neonates, infants, and pediatric patients has not been established.

Related Links:

T2 Biosystems
ASM 2015 presentation of study results


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.